Mizuho said the firm believes uniQure (QURE) shares are down likely due to a few factors, though it believes these factors are ultimately “non-issues.” The analyst cited the switch from propensity score weighting to propensity score measurement, though management said this is a non-issue and even a positive as FDA preference and recommendation is for PSM; some concerns about a delay in three-year data reading out in September, and; at-the-market filing may add pressure. The firm has a Neutral rating on uniQure.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QURE:
- Mizuho defends uniQure, says factors why it is down are ‘non-issues’
- uniQure’s Strategic Advancements and Regulatory Progress Lead to Buy Rating
- Positive Outlook for uniQure’s AMT-130 Program Amidst Upcoming 3-Year Data Release
- uniQure Announces $200 Million Sales Agreement
- uniQure reports Q2 EPS (69c), consensus (76c)